The *Mycobacterium tuberculosis* genotype family known as \"Beijing/W,\" \"W-Beijing,\" or \"Beijing\" is widespread ([@R1]*--*[@R3]). Described in 1995 as the prevalent genotype in East Asia ([@R4]), \>80% of strains from the Beijing area were of this type. The multidrug-resistant W strain is a member of the family. We use \"Beijing\" for the whole genotype family.

Researchers are concerned that the Beijing genotype may have a predilection for developing drug resistance ([@R5]) and may be spreading worldwide, perhaps as a result of increased virulence ([@R6]). A systematic review of the published literature in 2002 concluded that although Beijing genotype tuberculosis (TB) was widespread, associations with drug resistance varied, and little information on time trends was available ([@R2]).

The review highlighted the problems of relying on published literature: varying strain definitions; reporting bias; and limited information on selection criteria, population subgroups, age groups, or time trends. As part of the European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis, we have combined available datasets, using a common strain definition and individual-level data.

Methods
=======

Studies for inclusion were identified from the systematic review and from contacting members of the European Concerted Action and authors of relevant articles published since the review. We aimed to include as many studies as possible in which the proportion of TB caused by the Beijing genotype could be ascertained in an unbiased way. Studies could represent all or random samples of patients in an area, hospital, or laboratory. Studies limited to outbreaks, drug-resistant isolates, or of \<30 patients were excluded. A study description and individual patient data that included at least the year the case was diagnosed and the genotype were required.

Strain Classification
---------------------

Three methods identify Beijing genotype strains: spoligotyping ([@R7]), IS*6110* restriction fragment length polymorphism (RFLP) ([@R8]), and region A RFLP ([@R9]). The typical Beijing spoligotype shows hybridization to spacers 35--43. Beijing-like patterns with \<9 spacers (but not solely spacers 37--38, which represents *M. microti*), were included ([@R10]).

By using IS*6110* RFLP, fingerprints are compared to 19 patterns representative of the Beijing genotype (<https://hypocrates.rivm.nl/bnwww/index.html>). With standard techniques, allowing 1% position tolerance and classifying all matches \>80% as Beijing, these patterns have 96%--100% sensitivity and 98%--100% specificity to detect Beijing strains, taking spoligotyping as the accepted standard ([@R10]). Sensitivity is increased by spoligotyping strains with RFLP patterns that match 75%--80% to the reference strains. The third technique uses a characteristic IS*6110* insertion in region A. This method has 100% sensitivity and 98% specificity compared with spoligotyping ([@R10]).

Analysis
--------

The proportion of Beijing genotype strains in each study was calculated overall and after excluding immigrants. The proportion of Beijing genotype in immigrants was examined by place of birth. Time trends were examined directly and by examining trends with age; an association with younger age groups would suggest that the proportion of TB attributable to the Beijing genotype was increasing. Associations with drug resistance were examined, after immigrants were excluded, with and without excluding patients with previous TB. For pooled analyses, heterogeneity in the associations between studies was examined, and the results presented are adjusted for study.

Results
=======

Data were received from 49 studies representing 29,259 TB patients in 35 countries, including 11 studies from the systematic review ([@R2]); other studies in the review had no individual patient data available, used nonstandard case definitions, or researchers declined to participate. Other studies were contributed by members or contacts of the Concerted Action or were identified from subsequently published studies. Details of all included studies are shown in [Table A1](#TA.1){ref-type="table"}.

The proportion of tuberculosis due to the Beijing genotype in the included studies is shown in [Table A2](#TA.2){ref-type="table"}.

Overall, 9.9% had the Beijing genotype. In Western Europe and the Czech Republic, the proportion was low: \<6% of cases among nonimmigrants. In sub-Saharan Africa, the proportion was low except in Cape Town, South Africa. In Latin America, data were only available from Argentina and Brazil; both studies found \<1% of TB cases were caused by Beijing genotype. In North America and the Caribbean, the proportion was higher (8%--14%). In the former Soviet Union the proportion was high: 45%--56% in Russia and 29% in Estonia. The proportion was low in India (1%), higher in Bangladesh (7%), and increased further east: \>50% in many parts of Southeast and East Asia.

Analyses by region of birth showed similar patterns ([Table 1](#T1){ref-type="table"}). Beijing genotype strains were rare (0.5%) among immigrants from Eastern Europe other than the former Soviet Union; most came from the former Yugoslavia. The Beijing genotype was much less common among immigrants from the Indian subcontinent (3.4%) than among those from Southeast Asia (19%) or East Asia (58%). Beijing genotype strains were uncommon among immigrants from North Africa (3.0%), the Middle East (5.2%), and sub-Saharan Africa (2.2%, including 50 \[2.1%\] of 2,427 persons from Somalia). Among Middle Eastern immigrants, Beijing genotype was found in 6 (1%) of 620 persons from Turkey but in 8 (9.9%) of 81 from Afghanistan.

###### Proportion of tuberculosis patients due to the Beijing genotype by region of birth

  Region                       All patients, Beijing/total (%)   Immigrants only, Beijing/total (%)
  ---------------------------- --------------------------------- ------------------------------------
  Western Europe               272/9,496 (2.9)                   10/353 (2.8)
  Central and Eastern Europe   4/780 (0.5)                       3/562 (0.5)
  Former Soviet Union          244/590 (41.4)                    25/106 (23.6)
  Middle East                  62/1,165 (5.3)                    56/1,084 (5.2)
  North Africa                 30/991 (3.0)                      30/991 (3.0)
  Sub-Saharan Africa           275/6,816 (4.0)                   86/3,881 (2.2)
  Indian subcontinent          46/1,291 (3.6)                    38/1,111 (3.4)
  Southeast Asia               711/2,192 (32.5)                  154/811 (19.0)
  East Asia                    1,032/1,712 (60.3)                213/370 (57.6)
  Latin America                29/1,421 (2.0)                    21/457 (4.6)
  Caribbean                    31/320 (9.7)                      5/109 (4.6)
  North America                28/275 (10.2)                     1/15 (6.7)
  Australasia                  1/4 (25.0)                        1/4 (25.0)

Time Trends
-----------

Time trends were analyzed among nonimmigrants within individual studies with \>3 years of data ([Table 2](#T2){ref-type="table"}). (Studies from France, Iran, Thailand, Vietnam, and Spain are excluded because of small numbers in some years or absence of Beijing genotype strains).

###### Trends in proportion of tuberculosis cases due to the Beijing genotype over time among nonimmigrant populations\*

  Study                     Period       Earlier period,† Beijing/total (%)   Later period,† Beijing/total (%)   OR (95% CI) for change/y   p for linear trend by y
  ------------------------- ------------ ------------------------------------ ---------------------------------- -------------------------- -------------------------
  Western Austria           1993--2004   2/363 (0.6)                          5/310 (1.6)                        1.2 (0.9--1.5)             0.2
  Denmark                   1992--2001   7/885 (0.8)                          10/774 (1.3)                       1.1 (0.9--1.3)             0.4
  Finland                   2000--2002   2/414 (0.5)                          11/705 (1.6)                       1.7 (0.9--3.5)             0.1
  The Netherlands           1993--2002   91/1,862 (4.9)                       111/1,607 (6.9)                    1.1 (1.0--1.1)             0.004
  Western Sweden            1999--2002   0/34 (0.0)                           3/43 (7.0)                         3.1 (0.6--15)              0.2
  London, UK                1995--1997   9/200 (4.5)                          1/73 (1.4)                         0.7 (0.3--1.8)             0.4
  St. Petersburg, Russia    1999--2001   66/120 (55.0)                        67/116 (57.8)                      1.0 (0.7--1.3)             0.9
  Cape Town, South Africa   1992--1998   60/473 (12.7)                        80/374 (21.4)                      1.2 (1.1--1.3)             \<0.001
  Karonga, Malawi‡          1996--2003   12/460 (2.6)                         32/570 (5.6)                       1.2 (1.0--1.4)             0.03
  San Francisco, USA        1998--2000   6/50 (12.0)                          6/59 (10.2)                        1.0 (0.5--2.1)             1.0
  Buenos Aires, Argentina   1998--2001   1/188 (0.53)                         4/424 (0.94)                       1.0 (0.4--2.3)             1.0
  São Paulo, Brazil         2000--2002   2/268 (0.75)                         1/114 (0.88)                       1.0 (0.2--4.3)             1.0
  Okayama, Japan            2000--2002   42/56 (75.0)                         61/86 (70.9)                       0.8 (0.5--1.3)             0.4

\*OR, odds ratio; CI, confidence interval. †For each study, the period was split into 2 parts, earlier and later. ‡Includes immigrants from neighboring countries.

All Western European sites except London showed a slight increase in Beijing strains over time, but this finding was only significant in the Netherlands. Combining data for Western Europe, the odds ratio (OR), adjusted for study, for having the Beijing genotype in the later period compared to the earlier period was 1.5 (95% confidence interval \[CI\] 1.2--1.9). This figure was unchanged after adjusting for age. The trend was similar after excluding the Netherlands (adjusted OR 1.7, 95% CI 0.96--3.1).

In St. Petersburg, Okayama, Buenos Aires, São Paulo, and San Francisco, no significant change occurred over time, but the studies only covered a few years. In Cape Town and Malawi, significant increases occurred over time and were unchanged after adjusting for age.

Trends with Age
---------------

Trends with age for studies with \>3 cases of Beijing genotype TB among nonimmigrants are summarized in [Table 3](#T3){ref-type="table"}. Most Western European studies found the highest proportion of Beijing genotype TB in the youngest age groups. Overall, for Western Europe, compared to those age \>50 years, the OR, adjusted for study, of having the Beijing genotype was 1.2 (0.87--1.6) for those 30--49 years of age, and 2.4 (95% CI 1.8--3.3) for those \<30 years of age, p~trend~\<0.001. Excluding the Netherlands, the trend was stronger: adjusted OR 2.2 (95% CI 1.1--4.2) for those 30--49 years of age and 3.9 (95% CI 1.9--7.9) for those \<30 years of age, p~trend~\<0.001.

###### Proportion of tuberculosis cases caused by the Beijing genotype by age group of patient\*

  Study                       Age \<30 y, Beijing/total (%)   Age 30--49 y, Beijing/total (%)   Age \>50 y, Beijing/total (%)   p for trend    
  --------------------------- ------------------------------- --------------------------------- ------------------------------- -------------- ------
  Western Europe                                                                                                                               
                              Western Austria                 2/89 (2.3)                        45/214 (1.9)                    1/370 (0.3)    0.05
  Denmark                     4/210 (1.9)                     6/623 (1.0)                       7/826 (0.9)                     0.3            
  Finland                     2/35 (5.7)                      5/128 (3.9)                       6/931 (0.6)                     0.002          
  The Netherlands             70/703 (10.0)                   47/993 (4.7)                      85/1773 (4.8)                   \<0.001        
  Western Sweden              1/5 (20.0)                      1/7 (14.3)                        1/65 (1.5)                      0.05           
  United Kingdom                                                                                                                               
  Inner London                1/41 (2.4)                      2/67 (3.0)                        2/55 (3.6)                      0.7            
  London                      6/86 (7.0)                      1/104 (1.0)                       3/83 (3.7)                      0.2            
  Eastern Europe                                                                                                                               
                              Estonia                         14/43 (32.6)                      25/96 (26.0)                    15/52 (28.9)   0.7
  Russia                                                                                                                                       
  St. Petersburg              74/112 (66.1)                   61/111 (55.0)                     19/45 (42.2)                    0.02           
  Archangel†                  13/25 (52.0)                    32/77 (41.6)                      8/16 (50.0)                     0.8            
  Middle East                                                                                                                                  
                              Iran                            2/20 (10.0)                       2/25 (8.0)                      1/26 (3.9)     0.4
  Sub-Saharan Africa                                                                                                                           
                              Malawi‡                         19/341 (5.6)                      21/522 (4.0)                    4/167 (2.4)    0.08
  South Africa: Cape Town     51/299 (17.1)                   77/434 (17.7)                     11/111 (9.9)                    0.2            
  Zimbabwe: Harare            3/94 (3.2)                      1/102 (1.0)                       0/16 (0.0)                      0.2            
  North America                                                                                                                                
                              United States                                                                                                    
  New Jersey                  1/18 (5.6)                      11/62 (17.7)                      3/71 (4.2)                      0.2            
  San Francisco               1/21 (4.8)                      7/58 (12.1)                       4/30 (13.3)                     0.4            
  Caribbean                                                                                                                                    
                              Cuba                                                                                                             
  Not Havana                  10/48 (20.8)                    6/42 (14.3)                       6/70 (8.6)                      0.06           
  Havana                      1/11 (9.1)                      2/21 (9.5)                        1/19 (5.3)                      0.7            
  Latin America                                                                                                                                
                              Argentina: Buenos Aires         5/255 (2.0)                       0/224 (0.0)                     0/103 (0.0)    0.05
  Brazil: São Paulo           3/144 (2.1)                     0/187 (0.0)                       0/51 (0.0)                      0.1            
  Indian subcontinent                                                                                                                          
                              Bangladesh†                     3/20 (15.0)                       4/42 (9.5)                      0/35 (0.0)     0.03
  Southeast Asia                                                                                                                               
                              Indonesia: Jakarta              13/45 (28.9)                      14/33 (42.4)                    5/12 (41.7)    0.2
  Malaysia                    17/93 (18.3)                    20/129 (15.5)                     25/162 (15.4)                   0.6            
  Thailand: Bangkok           33/64 (51.6)                    41/88 (46.6)                      24/52 (46.2)                    0.5            
  Vietnam                                                                                                                                      
  Hanoi†                      11/15 (73.3)                    17/26 (65.4)                      9/23 (39.1)                     0.03           
  Ho Chi Minh City†           94/147 (64.0)                   134/265 (50.6)                    35/87 (40.2)                    \<0.001        
  Ho Chi Minh City            13/21 (61.9)                    17/40 (42.5)                      4/14 (28.6)                     0.04           
  Tien Giang                  4/7 (57.1)                      11/27 (40.7)                      13/26 (50.0)                    1.0            
  East Asia                                                                                                                                    
                              China                                                                                                            
  Shanghai and other areas†   5/5 (100.0)                     10/14 (71.4)                      16/24 (66.7)                    0.2            
  Henan                       10/19 (52.6)                    7/9 (77.8)                        16/21 (76.2)                    0.2            
  Hong Kong†                  95/151 (62.9)                   149/197 (75.6)                    112/152 (73.7)                  0.04           
  Japan: Okayama              9/12 (75.0)                     19/25 (76.0)                      75/105 (71.4)                   0.7            
  Mongolia                    50/95 (52.6)                    42/63 (66.7)                      5/10 (50.0)                     0.3            
  Taiwan†                     25/47 (53.2)                    36/83 (43.4)                      126/291 (43.3)                  0.3            

\*Studies with \>3 cases of Beijing genotype tuberculosis in nonimmigrants included. †Immigration status not known. ‡Immigrants from neighboring countries included.

In Russia and Estonia, Beijing genotype strains were more common in younger patients, and the trend was significant in St. Petersburg (p = 0.02). Overall, compared to those \>50 years of age, the study-adjusted OR was 1.1 (95% CI 0.70--1.8) for those 30--49 years of age and 1.7 (95% CI 1.1--2.9) for those \<30 years of age, p~trend~ = 0.02.

The African studies that found any Beijing strains noted a higher proportion in younger persons than in older persons. This difference was not significant in individual studies but was when studies were combined: adjusted OR, 1.9 (95% CI 1.1--3.4) for those 30--49 years of age and 2.1 (95% CI 1.2--3.7) for those \<30 years of age, compared to those \>50 years of age, p~trend~ = 0.03.

Among nonimmigrants in US studies, no significant trend occurred with age, either individually or overall. In Cuba, Beijing genotypes were more common in younger persons than in older persons in the larger study and overall (p~trend~ = 0.06). In Buenos Aires and São Paulo, all Beijing genotype--infected patients were \<30 years of age (p = 0.002).

Most Asian studies showed no association with age, but trends were seen in Bangladesh, Vietnam, and Hong Kong. In Vietnam, Beijing genotype was more common in younger patients in all 4 studies: overall, compared to those \>50 years of age, the study-adjusted OR was 1.5 (95% CI 1.0--2.2) for those 30--49 years of age and 2.7 (95% CI 1.7--4.2) for those \<30 years of age, p~trend~\<0.001. In Hong Kong, Beijing genotypes were least common in patients \<30 years of age.

Drug Resistance
---------------

Studies with drug resistance data for all or most patients and with \>3 Beijing genotype TB patients among nonimmigrants are summarized in [Table A3](#TA.3){ref-type="table"}. In the Western European studies, with the exception of inner London, resistance was more common among Beijing genotype strains than among other strains. Beijing genotype was significantly associated with resistance in Denmark (rifampin and ethambutol), Finland (rifampin and streptomycin), and the Netherlands (streptomycin). Overall, the study-adjusted OR for the association of Beijing genotype and resistance among nonimmigrants in Western Europe was 1.8 (95% CI 1.2--2.7) for any drug, 1.7 (95% CI 0.95--2.9) for isoniazid, 4.0 (95% CI 1.4--11.9) for rifampin, 2.3 (95% CI 1.4--3.7) for streptomycin, 3.0 (95% CI 0.38--23.2) for ethambutol, and 4.2 (95% CI 1.2--14.7) for multidrug resistance (i.e., resistance to at least isoniazid and rifampin). Of the Western European studies, only those from Denmark, Hamburg, the Netherlands, and London had data on previous treatment. After patients who had previously received treatment were excluded, the associations in the Netherlands and Denmark persisted, and the adjusted combined ORs were similar to those overall but with wider CIs (e.g., 1.6, 95% CI 1.0--2.6 for any drug resistance).

In Russia and Estonia, Beijing genotype was strongly associated with resistance to all tested drugs. None of the patients in Estonia had been previously treated. In the Archangel Oblast, the association persisted after previously treated patients were excluded, but in St. Petersburg only the association with isoniazid resistance remained significant. In Cuba, Beijing genotype was associated with streptomycin resistance in both studies, and this association persisted after previously treated patients were excluded.

In Malawi and Zimbabwe, none of the Beijing genotype isolates was drug resistant. In Cape Town, 14 (35%) of the 40 Beijing isolates that were tested were drug resistant, but the resistance of most Beijing isolates and of the other isolates was unknown.

In the Asian studies, only those in Bangladesh, Vietnam, and Taiwan found more drug resistance in Beijing genotype strains. In Bangladesh, 99% of the patients had previously received treatment for TB. In Vietnam, the results were little changed by excluding the few previously treated patients. In Taiwan, previous treatment was unknown. Two studies found that Beijing genotypes were less commonly drug resistant. In China, Beijing genotypes were less likely to exhibit ethambutol resistance; no information was available on previous treatment. In Malaysia, among patients without previous treatment, 1 (2%) of 48 isolates from patients with the Beijing genotype and 33 (13%) of 252 isolates from patients with other genotypes were resistant to any drugs (p = 0.03).

Other Associations
------------------

In most studies, the proportion of nonimmigrants with the Beijing genotype was similar for men and women. In Japan, the proportion was higher among men, and in Malawi, it was higher among women. Only 23 studies had data on HIV status in nonimmigrants, and of these, 13 found no Beijing genotype, no HIV-positive patients, or information was lacking on HIV status of the patients with Beijing genotype. In the 10 remaining studies (inner London, Lyon, the Netherlands, Tuscany, San Francisco, Cuba \[both studies\], Buenos Aires, Malawi, and Ho Chi Minh City), no association was found between HIV status and Beijing genotype.

No significant association was found between strain type and site of tuberculosis (pulmonary or extrapulmonary) in any of the 20 studies in which this information was available and both types of tuberculosis were included. In Cuba, outside Havana, and in the Archangel Oblast patients with recurrent TB were more likely than patients in their first episode of disease to have the Beijing genotype, but these associations were lost after adjusting for drug resistance. No associations with previous TB were found in any of the other 17 studies for which information was available, but the numbers of recurrent cases were often small.

Discussion
==========

In this study, we have brought together published and unpublished data to document the spread of Beijing genotype tuberculosis worldwide. Little information was available from many countries including most of the Americas, Eastern Europe, North Africa, the Middle East, and Australasia. All eligible studies were requested, whether Beijing genotypes were found or not, and within the included studies, the proportion with Beijing genotype should be representative of those settings. The individual-level data allowed comparable analyses in all sites and pooled analysis within regions. This study complements the spoligotype database ([@R3]), which includes only studies that used spoligotyping and is more inclusive and less detailed epidemiologically. The database shows a similar global distribution of the Beijing genotype to that described here.

The proportion of TB attributable to the Beijing genotype is variable: high in Asia, apart from the Indian subcontinent, increasing further east; low in parts of Africa, Latin America, and Western Europe; intermediate in the United States and Cuba; low in Eastern Europe (other than the former Soviet Union); low in the Middle East (including \<1% in a recent study from Tehran \[[@R11]\]). In Western Europe, Beijing genotype is more common among immigrant TB patients than among indigenous patients. The proportion of Beijing genotype TB among nonimmigrants may reflect the importance of immigrants to the total TB prevalence in these countries as well as the origin of these immigrants. Immigrants accounted for \>50% of TB cases in London, the Netherlands, France, Denmark, Sweden, and Hamburg, compared to 25% of cases in Italy, 24% in Austria, 8% in Finland, and 4% in Spain.

Using information from time and age group trends, we found that an increasing proportion of TB is due to Beijing genotype strains in Western Europe, southern Africa, and the former Soviet Union. We found little evidence of increase in Asia, except in Vietnam and Bangladesh.

Strong associations with drug resistance have been found in the former Soviet Union, Cuba, and Vietnam. The combined data for Western Europe suggest an association there. No association was found in a large study in Malawi or in most of the Asian studies.

When the data on trends and drug resistance presented here and from other studies are combined, the results suggest that the distribution of Beijing genotype TB has several patterns ([Figure](#F1){ref-type="fig"}). The Beijing genotype probably originated in the Beijing region of China ([@R1]*,*[@R4]); it was found in 90% of stored biopsy specimens in the 1950s, and this proportion has not changed over time ([@R12]). Beijing strains appear to have spread and become established as the predominant *M*. *tuberculosis* genotype in much of East and Southeast Asia, so little evidence of increase was found. In these areas, the Beijing genotype appears to be endemic and not associated with drug resistance (pattern 1).

![Distribution of Beijing genotype tuberculosis (TB). Size of circle indicates percentage of TB cases due to Beijing genotype; color in circle indicates drug sensitivity and distribution trend. Blue, pattern 1 (stable, no association with drug resistance); red, pattern 2 (increasing, associated with drug resistance); green, pattern 3 (increasing, drug sensitive); yellow, pattern 4 (absent); striped, trend or association with drug resistance not known.](05-0400-F){#F1}

In certain areas, including the former Soviet Union ([@R13]), Cuba, and Cape Town, epidemic spread was found, which was associated with drug resistance (pattern 2). Vietnam and Bangladesh follow this pattern, unlike most other Asian countries. Recent Indian studies suggest that India may also fit pattern 2 ([@R14]*,*[@R15]). In Taiwan, the association with drug resistance was not confirmed in a larger sample in 2003 (unpub. data), which suggests that it follows pattern 1. In parts of Western Europe, although the Beijing genotype remains uncommon, it appears to be increasing and is associated with drug resistance (pattern 2).

In the United States, the pattern is mixed. Nonimmigrant patients in San Francisco fit pattern 1: no association with drug resistance and no evidence of time trends. In this area, most Beijing isolates came from Asian immigrants, among whom no association was found between Beijing genotype and drug resistance. In the New Jersey study, no data on drug resistance were available, but a previous study in this area found that most Beijing isolates from nonimmigrants were pansusceptible ([@R1]*,*[@R16]). The age distribution does not suggest recent increase, which fits pattern 1. In contrast, the spread of the multidrug-resistant W strain in New York and beyond during the 1990s has been well documented ([@R17]*--*[@R19]). Other published studies from the United States confirm that the Beijing genotype is widespread but do not report drug resistance or trends ([@R20]*--*[@R23]).

In Malawi, an increase in the Beijing genotype over time was documented, but with drug sensitive strains (pattern 3). Argentina may fit this pattern, and spread of drug-sensitive Beijing genotype TB has been described in Gran Canaria ([@R24]). The final pattern (pattern 4) is of very low level or absent Beijing genotypes, as seen in parts of Africa and Europe.

The wide distribution of the Beijing genotype could be attributable to a founder effect or random drift, though these mechanisms would be unlikely to account for recent increases in multiple settings. The distribution could reflect particular stability of the genetic markers used to identify the genotype. High levels and epidemic spread may suggest that it transmits more easily or is more virulent than other strains. In vitro and animal studies have suggested increased multiplication or virulence for some Beijing strains ([@R6]*,*[@R25]) but not others ([@R26]). In Vietnam, the Beijing genotype was associated with treatment failure and relapse ([@R27]), but we found no such association. In Indonesia, patients with the Beijing genotype had a similar clinical picture to other TB patients for almost all parameters studied ([@R28]). In the Netherlands, the appearance on chest radiograph was similar for patients infected with Beijing genotype and for other TB patients ([@R29]). In Malawi, the Beijing genotype was not associated with death or transmissibility ([@R30]).

External factors may select for Beijing strains. In the former Soviet Union and the United States, spread has been associated with prisons and with high rates of drug resistance ([@R13]*,*[@R17]*,*[@R31]*,*[@R32]). In Mongolia, data were also available from prisoners. They had a higher proportion of Beijing genotype than did other patients, 46 (82%) of 56 compared to 97 (58%) of 168, p = 0.001, and a higher prevalence of drug resistance. Population movements ([@R33]), for example, from the former Soviet Union into Western Europe and through Afghanistan, may account for spread, recent increases, and the association with drug resistance ([@R34]).

Beijing genotypes may have a particular propensity to acquire drug resistance. Mutations in putative mutator genes have been found in Beijing genotypes, which suggests adaptability ([@R5]), but no increase in the rate of acquisition of resistance to rifampicin was found in in vitro studies ([@R35]). Once established, resistance could encourage spread if it delays effective treatment. Although the fitness of resistant strains is slightly reduced, this may be less marked for Beijing strains ([@R36]).

Conclusion
==========

This study has confirmed that Beijing genotype *M. tuberculosis* is an emerging infection in many parts of the world and is a highly endemic pathogen in other areas. Its association with drug resistance, sometimes at high levels, in a number of settings, underlines its importance. The reasons for its apparent success are not well understood but may depend on human population movements as well as on any intrinsic factors.
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###### Included studies on Beijing/W genotype *Mycobacterium tuberculosis* and drug resistance\*

  Country                        Period                                     Source                                                        Type of TB                                                   No previous TB %   Typing method    Reference†                
  ------------------------------ ------------------------------------------ ------------------------------------------------------------- ------------------------------------------------------------ ------------------ ---------------- ------------------------- -------------------
  Western Europe                                                                                                                                                                                                                                                     
                                 Austria: western                           1993--2004                                                    Laboratory receiving from nearly all hospitals in area       Pulm/Extra         ?                Spoligo on all            
  Denmark: entire                1992--2001                                 Central laboratory for entire country                         Pulm/Extra                                                   97                 RFLP, spoligo    ([@R37])                  
  Finland: entire                2000--2002                                 Central laboratory for entire country                         Pulm/Extra                                                   ?                  RFLP, spoligo    ([@R38])                  
  France                                                                                                                                                                                                                                                             
                                 Paris area                                 1995                                                          All patients from 10 hospitals                               Pulm/Extra         88               RFLP, spoligo             ([@R39])
  Paris                          2001--2003                                 Patients at 1 hospital                                        Pulm/Extra                                                   ?                  Spoligo on all                             
  Lyon                           2003                                       Central laboratory for area                                   Pulm/Extra                                                   77                 Spoligo on all                             
  Germany: Hamburg               2001                                       Notified patients in area                                     ?                                                            99                 RFLP, spoligo    ([@R40])                  
  Italy                                                                                                                                                                                                                                                              
                                 Verona                                     1996--1997                                                    Reference laboratory for area                                Pulm/Extra         ?                Spoligo on all            ([@R41])
  Sardinia                       1997--1998                                 Patients at 1 hospital                                        Pulm/Extra                                                   73                 RFLP, spoligo                              
  Tuscany                        2002                                       All patients in area                                          Pulm/Extra                                                   83                 RFLP, spoligo    ([@R42])                  
  Netherlands: entire            1993--2002                                 All patients in area                                          Pulm/Extra                                                   96                 RFLP, spoligo    ([@R43])                  
  Spain                                                                                                                                                                                                                                                              
                                 Elche                                      1993--1999                                                    Sample of patients in area                                   Pulm/Extra         90               RFLP, spoligo             ([@R44])
  Madrid                         1992--2001                                 All patients in area                                          Pulm/Extra                                                   71                 RFLP, spoligo                              
  Zaragoza                       1993--1995                                 All patients in area                                          Pulm/Extra                                                   ?                  RFLP, spoligo    ([@R45])                  
  Sweden: western                1999--2002                                 Laboratory for all patients in area                           Pulm/Extra                                                   87                 Spoligo on all   ([@R46])                  
  United Kingdom                                                                                                                                                                                                                                                     
                                 Inner London                               1993                                                          Laboratories for all patients in area                        Pulm/Extra         89               Spoligo on all            ([@R47])
  London                         1995--1997                                 Laboratories for all patients in area                         Pulm/Extra                                                   88                 RFLP             ([@R48])                  
  Central and Eastern Europe                                                                                                                                                                                                                                         
                                 Czech Republic: Prague and South Moravia   1998                                                          Laboratories for all patients in areas                       Pulm/Extra         ?                Spoligo on all            ([@R49])
  Estonia: entire                1994                                       All new pulmonary TB patients in area                         Pulm                                                         100                RFLP, spoligo    ([@R50])                  
  Russia                                                                                                                                                                                                                                                             
                                 St. Petersburg                             1999--2002                                                    All patients in area with data                               Pulm/Extra         59               RFLP, spoligo             ([@R51]*,*[@R52])
  Archangel                      1998--1999                                 All patients at TB clinic                                     Pulm                                                         75                 Spoligo on all   ([@R53])                  
  North Africa and Middle East                                                                                                                                                                                                                                       
                                 Iran: several areas                        1995--1997                                                    All smear-positive patients from Shiraz plus random others   Pulm/Extra         79               RFLP, spoligo             ([@R54])
  Sub-Saharan Africa                                                                                                                                                                                                                                                 
                                 Cameroon: western region                   1997--1998                                                    All patients from all hospitals in region                    Pulm               79               Spoligo on all            ([@R55],[@R56])
  Ethiopia: Addis Ababa          1996                                       Patients at 1 hospital                                        Pulm                                                         85                 RFLP, spoligo    ([@R57])                  
  Guinea Bissau: Bissau          1989--1993                                 All patients in area                                          Pulm                                                         100                RFLP, spoligo    ([@R58])                  
  Malawi: Karonga District       1996--2003                                 All patients in area                                          Pulm/Extra                                                   93                 RFLP, spoligo    ([@R59])                  
  South Africa: Cape Town        1992--1998                                 All patients from 2 clinics                                   Pulm/Extra                                                   91                 RFLP, spoligo    ([@R60])                  
  Sudan: Khartoum                1998--1999                                 Patients from 2 clinics                                       Pulm                                                         54                 Spoligo on all   ([@R61])                  
  Zimbabwe: Harare               1997                                       All patients from 1 hospital                                  Pulm                                                         93                 Spoligo on all   ([@R62])                  
  North America                                                                                                                                                                                                                                                      
                                 United States                                                                                                                                                                                                                       
                                 New Jersey                                 1999                                                          All patients in area                                         Pulm/Extra         99               RFLP, spoligo, region A   ([@R63])
  San Francisco                  1998--2000                                 All patients in area                                          Pulm/Extra                                                   92                 RFLP             ([@R64])                  
  Caribbean                                                                                                                                                                                                                                                          
                                 Cuba                                                                                                                                                                                                                                
                                 Outside Havana                             1994--1995                                                    Isolates sent from regional laboratories                     Pulm               94               RFLP, spoligo             ([@R65])
  Havana                         1997--1998                                 Isolates sent to reference laboratory                         Pulm                                                         86                 RFLP             ([@R66])                  
  Latin America                                                                                                                                                                                                                                                      
                                 Argentina: Buenos Aires                    1998--2001                                                    All patients in 1 hospital                                   Pulm/Extra         82               Spoligo on all            
  Brazil: São Paulo              2000--2002                                 All patients in area                                          Pulm                                                         72                 RFLP                                       
  Indian subcontinent                                                                                                                                                                                                                                                
                                 India: Delhi                               1995--1996                                                    Patients from 2 male wards + clinic                          ?                  57               RFLP, spoligo             ([@R67])
  Bangladesh: Mymensingh         2001--2003                                 Hospitalized patients, 3 hospitals                            Pulm                                                         1                  Spoligo on all   ([@R68])                  
  Southeast Asia                                                                                                                                                                                                                                                     
                                 Indonesia: Jakarta                         1998--1999                                                    All patients from outpatient TB clinic                       Pulm               75               RFLP,spoligo              ([@R69])
  Malaysia: entire               1993--1994                                 Random sample from reference laboratory                       Pulm/Extra                                                   89                 RFLP             ([@R70])                  
  Thailand: Bangkok              1998--2000                                 All patients in single hospital                               Pulm/Extra                                                   Spoligo on all     ([@R71])                                   
  Vietnam                                                                                                                                                                                                                                                            
                                 Hanoi, Ho Chi Minh City                    1998--1999                                                    All new smear-positive patients at 2 centers                 Pulm               ?                Spoligo on all            ([@R72])
  Ho Chi Minh City               1998--2000                                 HIV stratified random sample (1/3 HIV positive)               Pulm                                                         100                RFLP, spoligo                              
  Tiet Giang Province            2003                                       Age stratified sample from laboratory (1/2 patients \<40 y)   Pulm                                                         93                 RFLP, spoligo                              
  East Asia                                                                                                                                                                                                                                                          
                                 China                                                                                                                                                                                                                               
                                 Shanghai and other areas                   1994--1995                                                    Random sample from laboratory                                ?                  ?                Spoligo on all            
                                 Henan                                      2001--2002                                                    All patients in 1 hospital (severe cases)                    Pulm               87               RFLP                      
  Hong Kong: Hong Kong           1998--1999                                 Random sample from laboratory                                 ?                                                            100                Spoligo on all   ([@R73])                  
  Japan: Okayama                 2000--2002                                 All patients in area with data                                Pulm/Extra                                                   99                 RFLP, spoligo    ([@R74])                  
  Mongolia: entire               1998--1999                                 Random sample of patients in area                             Pulm                                                         100                Spoligo on all   ([@R75])                  
  Taiwan: entire                 2002                                       Random sample from laboratory                                 Pulm/Extra                                                   ?                  Spoligo on all   ([@R76])                  

\*TB, tuberculosis; Pulm, pulmonary; extra, extrapulmonary; spoligo, spoligotyping; RFLP, restriction fragment length polymorphism, IS*6110* fingerprinting; region A, characteristic insertion in region A. †The references given describe the studies from which the data came. In many cases, the analysis of Beijing strains has been carried out specifically for this collaborative study. The key contacts who contributed the data are listed as follows: Austria: Wolfgang Prodinger (Medizinische Universität Innsbruck); Denmark: Troels Lillebaek (Statens Serum Institut, Copenhagen); Finland: Hanna Soini, Petri Ruutu, (National Public Health Institute, Helsinki); France: Cristina Gutierrez, Veronique Vincent (Institut Pasteur, Paris); Beate Heym, Veronique Friocourt (Hôpital Ambroise Paré, Boulogne-Billancourt*)*; Isabelle Fredenucci, Jean-Pierre Flandrois (Centre Hospitalier Lyon-Sud, Lyon); Germany: Stefan Niemann (National Reference Centre for Mycobacteria, Forschungszentrum Borstel, Hamburg), Roland Diel (School of Public Health, University of Düsseldorf); Italy: Stefano Bonora (Università di Verona); Leonardo A Sechi, Stephania Zanetti (Università di Sassari); Carlo Garzelli (Università di Pisa); the Netherlands: Martien Borgdorff (KNCV Tuberculosis Foundation) Petra de Haas, Kristin Kremer, Dick van Soolingen (RIVM); Spain: Montserrat Ruiz, Juan Carlos Rodríguez, Gloria Royo (Universidad Miguel Hernández, Elche); Ana Pérez Meixeira, Jenaro Astray (Public Health Institute Getafe, Madrid), Juana Cacho, Amador Ramos (Hospital Universitario de Getafe); Maria Jose Iglesias (University of Zaragoza), Sofia Samper (Hospital Universitario Miguel Servet, Zaragoza); United Kingdom: Andrew Hayward, John Watson, Francis Drobniewski (Health Protection Agency, London); Jeremy Dale (University of Surrey) on behalf of the Steering Committee, Molecular Epidemiology of Tuberculosis in London; Sweden: Malin Ridell, Liselott Svensson (Institute of Medical Microbiology and Immunology, Göteborg University); Czech Republic: Milan Kubin (Institute of Hygiene of the City of Prague); Estonia: Annika Krüüner (Tartu University, Estonia, and Karolinska Institute, Stockholm, Sweden); Russia: Olga Toungoussova (University of Oslo, Norway), Dominique Caugant (Norwegian Institute of Public Health, Oslo, Norway), Andrey Mariandyshev (Northern State Medical University, Archangel): Olga Narvaskaya, Igor Mokrousov (St. Petersburg Pasteur Institute), Tatjana Otten, Boris Vyshnevskiy (Research Institute of Phthisiopulmonology, St. Petersburg); Iran: Mehrnoosh Doroudchi (Shiraz University of Medical Sciences); Cameroon: Sara Ngo Niobe-Eyangoh (Centre Pasteur du Cameroun, Yaoundé); Ethiopia: Judith Bruchfeld (Swedish Institute for Infectious Disease Control, Solna); Guinea Bissau: Tuija Koivula, Gunilla Kallenius (Swedish Institute for Infectious Disease Control, Solna); Malawi: Amelia Crampin, Judith Glynn (London School of Hygiene and Tropical Medicine, UK) on behalf of The Karonga Prevention Study (Chilumba, Malawi); South Africa: Madalene Richardson, Paul van Helden, Rob Warren, Nulda Beyers (Stellenbosch University, Cape Town); Sudan: Ghada Sharaf-Eldin (National Health Laboratory, Khartoum); Zimbabwe: Philippa Easterbrook, Shahed Murad, Francis Drobniewski (King's College London, UK); Cuba: Raul Diaz (Instituto Pedro Kourí, Havana); United States: Barry Kreiswirth (International Center for Public Health, Newark, NJ); Midori Kato-Maeda, Elizabeth Fair, Sebastien Gagneux, Peter Small (Stanford University, Stanford, CA); Argentina: Nora Morcillo (Reference Laboratory of Buenos Aires Tuberculosis Control Program) Angel Cataldi (National Institute of Agricultural Technology); Brazil: Lucilaine Ferrazoli (Instituto Adolfo Lutz, Sao Paulo); India: Kristin Kremer (RIVM), P. Seth (All India Institute of Medical Sciences, New Delhi); Bangladesh: Leen Rigouts, Isdore Chola Shamputa (Institute of Tropical Medicine, Antwerp, Belgium); Indonesia: Reinout van Crevel (University Medical Center Nijmegen, the Netherlands); Malaysia: Jeremy Dale (University of Surrey, Guildford, UK); Thailand: Wolfgang Prodinger (Medizinische Universität Innsbruck, Austria), Porntip Bunyaratevej (Mahidol University, Bangkok); China: James Douglas (University of Hawaii); Li Weimin (Beijing Tuberculosis and Chest Tumor Institution), Kristin Kremer (RIVM); K.M. Kam (Tuberculosis Reference Laboratory, Hong Kong); Japan: Ritsuko Ohata (Okayama Prefectural Institute for Environmental Science and Public Health); Mongolia: N. Naranbat (National Center for Communicable Diseases, Ulaanbaatar); Vietnam: Dang Duc Anh (National Institute of Hygiene and Epidemiology, Hanoi); Mai Huyen, Nguyen Thi Ngoc Lan (Ho Chi Minh City); Taiwan: Ruwen Jou (Center for Disease Control, Taipei).

###### Proportion of tuberculosis cases caused by the Beijing genotype in different studies

  Study                          Period                      Overall Beijing/total (%)   Excluding immigrants,\* Beijing/total (%)   
  ------------------------------ --------------------------- --------------------------- ------------------------------------------- --------------
  Western Europe                                                                                                                     
                                 Austria: western            1993--2004                  12/895 (1.3)                                7/673 (1.0)
  Denmark: entire                1992--2001                  96/3,844 (2.5)              17/1,659 (1.0)                              
  Finland: entire                2000--2002                  23/1,246 (1.9)              13/1,119 (1.2)                              
  France                                                                                                                             
  Paris area                     1995                        3/272 (1.1)                 0/91 (0.0)                                  
  Paris                          2001--2003                  5/66 (7.6)                  1/22 (4.6)                                  
  Lyon                           2003                        3/85 (3.5)                  1/31 (3.2)                                  
  Germany: Hamburg               2001                        6/178 (3.4)                 1/80 (1.3)                                  
  Italy                                                                                                                              
  Verona                         1996--1997                  2/158 (1.3)                 0/131 (0.0)                                 
  Sardinia                       1997--1998                  2/350 (0.6)                 0/28 (0.0)                                  
  Tuscany                        2002                        7/245 (2.9)                 2/153 (1.2)                                 
  Netherlands: entire            1993--2002                  522/8,510 (6.1)             202/3,469 (5.8)                             
  Spain                                                                                                                              
  Elche                          1993--1999                  0/146 (0.0)                                                             
  Madrid                         1992--2001                  0/507 (0.0)                 0/484 (0.0)                                 
  Zaragoza                       1993--1995                  2/569 (0.4)                 0/544 (0.0)                                 
  Sweden: western                1999--2002                  11/212 (5.2)                3/77 (3.9)                                  
  United Kingdom                                                                                                                     
  Inner London                   1993                        18/547 (3.3)                5/164 (3.0)                                 
  London                         1995--1997                  108/2,490 (4.3)             10/273 (3.7)                                
  Central and Eastern Europe                                                                                                         
                                 Czech Republic                                                                                      
  Prague                         1998                        2/111 (1.8)                 1/104 (1.0)                                 
  South Moravia                  1998                        5/120 (4.2)                 0/114 (0.0)                                 
  Estonia: entire                1994                        61/209 (29.2)               61/209 (29.2)                               
  Russia                                                                                                                             
  St. Petersburg                 1999--2001                  133/236 (56.4)              133/236 (56.4)                              
  Archangel                      1998--1999                  54/119 (45.4)                                                           
  North Africa and Middle East                                                                                                       
                                 Iran: several areas         1995--1997                  10/101 (9.9)                                6/81 (7.4)
  Sub-Saharan Africa                                                                                                                 
                                 Cameroon†: western region   1997--1998                  0/456 (0.0)                                 0/456 (0.0)
  Ethiopia: Addis Ababa          1996                        0/121 (0.0)                 0/121 (0.0)                                 
  Guinea Bissau: Bissau          1989--1993                  1/229 (0.4)                 1/221 (0.5)                                 
  Malawi: Karonga District       1996--2003                  44/1,030 (4.3)              38/785 (4.8)                                
  South Africa: Cape Town        1992--1998                  140/847 (16.5)              140/847 (16.5)                              
  Sudan: Khartoum                1998--1999                  0/49 (0.0)                  0/48 (0.0)                                  
  Zimbabwe: Harare               1997                        4/214 (1.9)                 4/212 (1.9)                                 
  North America                                                                                                                      
                                 United States                                                                                       
  New Jersey                     1999                        29/382 (7.6)                15/151 (9.9)                                
  San Francisco                  1998--2000                  135/492 (27.4)              12/109 (11.0)                               
  Caribbean                                                                                                                          
                                 Cuba                                                                                                
  Outside Havana                 1994--1995                  22/160 (13.8)               22/160 (13.8)                               
  Havana                         1997--1998                  4/51 (7.8)                  4/51 (7.8)                                  
  Latin America                                                                                                                      
                                 Argentina: Buenos Aires     1998--2001                  5/612 (0.8)                                 5/582 (0.9)
  Brazil: São Paulo              2000--2001                  4/420 (1.0)                 3/382 (0.8)                                 
  Indian subcontinent                                                                                                                
                                 India: Delhi                1995--1996                  1/83 (1.2)                                  
  Bangladesh: Mymensingh         2000--2002                  7/97 (7.2)                                                              
  Southeast Asia                                                                                                                     
                                 Indonesia: Jakarta          1998--1999                  32/91 (35.2)                                32/91 (35.2)
  Malaysia: Sample               1993--1994                  71/426 (16.7)               65/388 (16.8)                               
  Thailand: Bangkok              1998--2000                  98/204 (48.0)               98/204 (48.0)                               
  Vietnam                                                                                                                            
  Hanoi                          1998--1999                  37/64 (57.8)                                                            
  Ho Chi Minh City               1998--1999                  263/499 (52.7)                                                          
  Ho Chi Minh City               1998--2000                  34/75 (45.3)                34/75 (45.3)                                
  Tien Giang                     2003                        28/60 (46.7)                28/60 (46.7)                                
  East Asia                                                                                                                          
                                 China                                                                                               
  Shanghai and other areas       1994--1995                  40/59 (67.8)                                                            
  Henan                          2000--2001                  36/52 (69.2)                36/52 (69.2)                                
  Hong Kong: Hong Kong           1998--1999                  356/500 (71.2)                                                          
  Japan: Okayama                 2000--2002                  103/142 (72.5)              103/142 (72.5)                              
  Mongolia: entire               1998--1999                  97/168 (57.7)               97/168 (57.7)                               
  Taiwan: entire                 2002                        187/421 (44.4)                                                          

\*Immigration status not known for all patients. †The spoligotype of 1 isolate in this study had only spacers 40--43, but other genetic markers showed it to be *Mycobacterium africanum*.

###### Drug resistance in Beijing and other genotypes of Mycobacterium tuberculosis among nonimmigrants\*†

  Study                     n       \% resistant to each drug (no.)                                                       
  ------------------------- ------- --------------------------------- ------------ ------------ ------------ ------------ ------------
  West Europe                                                                                                             
  Austria: western                                                                                                        
  Beijing                   7       14.3 (1)                          0.0 (0)      14.3 (1)     0.0 (0)      0.0 (0)      0.0 (0)
  Other                     647     6.7 (43)                          2.9 (19)     2.2 (14)     3.9 (25)     0.78 (5)     0.93 (6)
  Denmark                                                                                                                 
  Beijing                   16      12.5 (2)                          12.5 (2)     6.3 (1)      12.5 (2)     6.3 (1)      6.3 (1)
  Other                     1,623   10.2 (165)                        3.1 (50)     0.12 (2)‡    3.6 (58)     0.0 (0)§     0.0 (0)§
  Finland                                                                                                                 
  Beijing                   13      15.4 (2)                          7.7 (1)      7.7 (1)      16.7 (2)     0.0 (0)      7.7 (1)
  Other                     1,102   4.6 (51)                          1.5 (17)     0.27 (3)‡    1.2 (12)§    0.73 (5)     0.0 (0)‡
  The Netherlands                                                                                                         
  Beijing                   199     9.1 (18)                          3.5 (7)      0.50 (1)     7.0 (14)                  0.50 (1)
  Other                     3,239   5.8 (189)                         3.2 (105)    0.22 (7)     3.9 (125)‡   0.15 (5)     
  Western Sweden                                                                                                          
  Beijing                   3       33.3 (1)                          33.3 (1)     0.0 (0)      33.3 (1)     0.0 (0)      0.0 (0)
  Other                     72      5.6 (4)                           2.8 (2)      0.0 (0)      1.4 (1)      0.0 (0)      0.0 (0)
  United Kingdom                                                                                                          
  Inner London                                                                                                            
  Beijing                   5       0.0 (0)                           0.0 (0)      0.0 (0)                   0.0 (0)      
  Other                     145     2.8 (4)                           2.1 (3)      0.69 (1)     0.69 (1)                  
  London                                                                                                                  
  Beijing                   10      20.0 (2)                          20.0 (2)     0.0 (0)      10.0 (1)     0.0 (0)      0.0 (0)
  Other                     259     11.2 (29)                         9.3 (24)     3.5 (9)      4.3 (11)     1.2 (3)      3.5 (9)
  Eastern Europe                                                                                                          
  Estonia                                                                                                                 
  Beijing                   61      70.5 (43)                         59.0 (36)    34.4 (21)    59.0 (36)    19.7 (12)    34.4 (21)
  Other                     148     14.2 (21)¶                        8.8 (13)¶    2.7 (4)¶     8.1 (12)¶    1.4 (2)¶     2.0 (3)¶
  Russia                                                                                                                  
  St. Petersburg                                                                                                          
  Beijing                   133     90.2 (120)                        74.4 (99)    67.7 (90)    86.5 (115)   12.0 (16)    60.2 (80)
  Other                     103     74.8 (77)§                        52.4 (54)¶   47.6 (49)§   70.9 (73)§   2.9 (3)§     42.7 (44)§
  Archangel\#                                                                                                             
  Beijing                   54      79.6 (43)                         64.8 (35)    46.3 (25)    75.9 (41)    44.4 (24)    46.3 (25)
  Other                     65      36.9 (24)¶                        30.8 (20)¶   7.7 (5)¶     23.1 (15)¶   21.5 (14)§   7.7 (5)
  Sub-Saharan Africa                                                                                                      
  Malawi\*\*                                                                                                              
  Beijing                   43      0.0 (0)                           0.0 (0)      0.0 (0)      0.0 (0)      0.0 (0)      0.0 (0)
  Other                     964     6.6 (64)                          6.2 (60)     0.6 (6)      5.7 (24)     0.47 (2)     0.6 (6)
  United States                                                                                                           
  San Francisco                                                                                                           
  Beijing                   12      8.3 (1)                           8.3 (1)      8.3 (1)      8.3 (1)      8.3 (1)      8.3 (1)
  Other                     96      16.7 (16)                         2.1 (2)      3.1 (3)      11.5 (11)    1.0 (1)      0.0 (0)
  Caribbean                                                                                                               
  Cuba                                                                                                                    
  Outside Havana                                                                                                          
  Beijing                   22      50.0 (11)                         0.0 (0)      9.1 (2)      50.0 (11)    0.0 (0)      0.0 (0)
  Other                     136     6.6 (9)¶                          2.9 (4)      1.5 (2)      4.4 (6)¶     0.7 (1)      1.5 (2)
  Havana                                                                                                                  
  Beijing                   4       50.0 (2)                          0.0 (0)      0.0 (0)      50.0 (2)     0.0 (0)      0.0 (0)
  Other                     47      4.3 (2)‡                          0.0 (0)      0.0 (0)      4.3 (2)‡     0.0 (0)      0.0 (0)
  Latin America                                                                                                           
  Argentina: Buenos Aires                                                                                                 
  Beijing                   5       0.0 (0)                           0.0 (0)      0.0 (0)      0.0 (0)      0.0 (0)      0.0 (0)
  Other                     548     29.0 (159)                        22.5 (123)   15.0 (82)    18.3 (100)   9.1 (50)     14.6 (80)
  Brazil: São Paulo                                                                                                       
  Beijing                   4       50.0 (2)††                        50.0 (2)     50.0 (2)     50.0 (2)     0 (0.0)      50.0 (2)
  Other                     416     15.1 (63)                         9.9 (41)     6.3 (26)‡    3.4 (14)§    2.4 (10)     4.8 (20)‡
  Indian subcontinent                                                                                                     
  Bangladesh                                                                                                              
  Beijing                   7       71.4 (5)                          71.4 (5)     28.6 (2)     42.9 (3)     28.6 (2)     28.6 (2)
  Other                     89      20.2 (18)§                        14.6 (13)§   4.5 (4)      12.4 (11)    1.1 (1)‡     3.4 (3)‡
  Southeast Asia                                                                                                          
  Indonesia: Jakarta                                                                                                      
  Beijing                   28      35.7 (10)                         35.7 (10)    7.1 (2)      14.3 (4)     3.6 (1)      7.1 (2)
  Other                     53      22.6 (12)                         17.0 (9)     3.8 (2)      5.7 (3)      5.7 (3)      3.8 (2)
  Malaysia                                                                                                                
  Beijing                   64      6.3 (4)                           3.1 (2)      3.1 (2)      4.7 (3)      3.1 (2)      3.1 (2)
  Other                     322     14.9 (48)                         8.7 (28)     3.7 (12)     8.7 (28)     2.2 (7)      3.1 (10)
  Thailand: Bangkok                                                                                                       
  Beijing                   98      29.6 (29)                         12.2 (12)    7.1 (7)      20.4 (20)    3.1 (3)      4.1 (4)
  Other                     106     31.1 (33)                         5.7 (6)      5.7 (6)      18.9 (20)    6.6 (7)      0.9 (1)
  Vietnam                                                                                                                 
  Hanoi\#                                                                                                                 
  Beijing                   33      60.6 (20)                         60.6 (20)    36.4 (12)    39.4 (13)    21.2 (7)     36.4 (12)
  Other                     20      25.9 (7)§                         22.2 (6)§    11.1 (3)‡    7.4 (2)§     3.7 (1)      7.4 (2)§
  Ho Chi Minh 1\#                                                                                                         
  Beijing                   81      43.2 (35)                         27.2 (22)    6.2 (5)      42.0 (34)    6.2 (5)      6.2 (5)
  Other                     87      26.4 (23)‡                        19.5 (17)    2.3 (2)      17.2 (15)¶   2.3 (2)      2.3 (2)
  Ho Chi Minh 2                                                                                                           
  Beijing                   34      52.9 (18)                         41.2 (14)    5.9 (2)      50.0 (17)    0.0 (0)      5.9 (2)
  Other                     41      34.2 (14)                         22.0 (9)     4.9 (2)      24.4 (10)‡   0.0 (0)      4.9 (2)
  Tien Giang                                                                                                              
  Beijing                   28      53.6 (15)                         21.4 (6)     7.1 (2)      53.6 (15)    3.6 (1)      7.1 (2)
  Other                     32      34.4 (11)                         15.6 (5)     0.0 (0)      28.1 (9)‡    0.0 (0)      0.0 (0)
  East Asia                                                                                                               
  China                                                                                                                   
  Shanghai\#                                                                                                              
  Beijing                   25      44.0 (11)                         28.0 (7)     16.0 (4)     30.4 (7)     0.0 (0)      16.0 (4)
  Other                     14      57.1 (8)                          35.7 (5)     14.3 (2)     35.7 (5)     21.4 (3)‡    14.3 (2)
  Henan                                                                                                                   
  Beijing                   36      33.3 (12)                         25.0 (9)     16.7 (6)     27.8 (10)    8.3 (3)      13.9 (5)
  Other                     16      31.3 (5)                          18.9 (3)     6.3 (1)      25.0 (4)     0.0 (0)      6.3 (1)
  Hong Kong                                                                                                               
  Beijing                   356     13.5 (48)                         5.3 (19)     0.6 (2)      9.3 (33)     1.1 (4)      0.6 (2)
  Other                     144     18.1 (26)                         8.3 (12)     0.7 (1)      13.9 (20)    1.4 (2)      0.7 (1)
  Mongolia                                                                                                                
  Beijing                   97      48.5 (47)                         27.8 (27)    2.1 (2)      39.2 (38)    4.1 (4)      2.1 (2)
  Other                     71      50.7 (36)                         16.9 (12)    0.0 (0)      46.5 (33)    0.0 (0)      0.0 (0)
  Taiwan\#                                                                                                                
  Beijing                   181     49.7 (90)                         33.7 (61)    21.0 (38)    21.0 (38)    27.1 (49)    19.3 (35)
  Other                     172     35.5 (61)§                        24.4 (42)    15.7 (27)    19.8 (34)    16.9 (29)‡   15.7 (27)

\*Studies with \>3 patients with Beijing genotype tuberculosis with known drug sensitivity included. In all but 3 of the included studies, \>97% of patients were tested for drug resistance. The 3 exceptions were Argentina (95%), inner London (91%), and Jakarta (79%). In some studies, not all patients were tested for every drug. In some studies, \"any drug\" includes drugs not shown on the table (e.g., pyrazinamide). In Zimbabwe, 0/4 patients with Beijing genotype strains had drug- resistant strains; whether other strains were resistant is unknown. †MDR, multidrug resistant, resistant to at least isoniazid and rifampin. ‡p\<0.05. §p\<0.01. ¶p\<0.001. \#Immigration status not known. \*\*Includes immigrants from neighboring countries. ††The 2 patients with drug-resistant Beijing strains in this study were brothers.
